28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
10
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.
Schrodinger, Inc.
11
Discovery of Small Molecules that Bind to Son of Sevenless 2 (SOS2).
Vanderbilt University School of Medicine
37
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Bayer AG
13
Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
China Pharmaceutical University
14
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.
Tianjin University of Science & Technology
4
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer.
China Pharmaceutical University
2
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo.
East China University of Science and Technology
2
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.
Ocean University of China
4
Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor.
Nanjing University of Chinese Medicine
48
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery.
Sichuan University
14
Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling.
Sun Yat-Sen University
14
Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.
China Pharmaceutical University
6
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Mirati Therapeutics
7
Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors.
Jiangnan University
8
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers.
Shanghai Institute of Materia Medica
25
Design, Synthesis, and Bioevaluation of Pyrido[2,3-
Nanjing University of Chinese Medicine
33
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Mirati Therapeutics
18
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
Wuhan University of Science and Technology
13
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Boehringer Ingelheim Rcv
49
Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods.
Vanderbilt University School of Medicine
42
Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS.
Vanderbilt University School of Medicine
65
Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Boehringer Ingelheim Rcv
40
Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling.
Vanderbilt University
12
SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
Department Of Health
121
PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS
King''s College London